IP Library › Granted Patent US 12,734,147
Granted Patent B2
US 12,734,147 · App. 18/497,850 · Granted Sep 15, 2026

Neurodevelopmental disorder therapy

Inventor: Christopher U. Missling (New York, NY)
Assignee: Anavex Life Sciences Corp.
A61K31/341A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,734,147
App. No.
18/497,850
Granted
Sep 15, 2026
Kind
B2
Abstract

This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.

Claims (20)

1 . A method of treating Rett syndrome in a subject by administering to said subject a composition comprising a therapeutically effective amount of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (A2-73); wherein the therapeutically effective amount is a dosage from about 0.5 mg/day to about 100 mg/day; and wherein the composition is selected from an oral composition, a transdermal composition, a parenteral composition, and an intravenous composition.

2 . The method of claim 1 , wherein the composition is an oral composition and the dosage is from about 1 mg/day to about 60 mg/day.

3 . The method of claim 2 , wherein the composition is an oral composition and the dosage is from about 20 mg/day to about 50 mg/day.

4 . The method of claim 3 , wherein the composition is an oral composition and the dosage is from about 30 mg/day to about 40 mg/day.

5 . The method of claim 1 , wherein the composition is an oral composition and the dosage is from about 0.5 mg/day to about 20 mg/day.

6 . The method of claim 1 , wherein the composition is a transdermal composition and the dosage is from about 1 mg/day to about 60 mg/day.

7 . The method of claim 6 , wherein the composition is a transdermal composition and the dosage is from about 20 mg/day to about 50 mg/day.

8 . The method of claim 7 , wherein the composition is a transdermal composition and the dosage is from about 30 mg/day to about 40 mg/day.

9 . The method of claim 1 , wherein the composition is a transdermal composition and the dosage is from about 0.5 mg/day to about 20 mg/day.

10 . The method of claim 1 , wherein the composition is a parenteral composition and the dosage is from about 1 mg/day to about 60 mg/day.

11 . The method of claim 10 , wherein the composition is a parenteral composition and the dosage is from about 20 mg/day to about 50 mg/day.

12 . The method of claim 11 , wherein the composition is a parenteral composition and the dosage is from about 30 mg/day to about 40 mg/day.

13 . The method of claim 1 , wherein the composition is a parenteral composition and the dosage is from about 0.5 mg/day to about 20 mg/day.

14 . The method of claim 1 , wherein the composition is an intravenous composition and the dosage is from about 1 mg/day to about 60 mg/day.

15 . The method of claim 14 , wherein the composition is an intravenous composition and the dosage is from about 20 mg/day to about 50 mg/day.

16 . The method of claim 14 , wherein the composition is an intravenous composition and the dosage is from about 30 mg/day to about 40 mg/day.

17 . The method of claim 1 , wherein the composition is an intravenous composition and the dosage is from about 0.5 mg/day to about 20 mg/day.

18 . The method of claim 1 , wherein the composition is administered to the subject for a period of at least 5 days, at least 10 days, at least 15 days, at least 60 days, at least 6 months, a least 1 year, at least 2 years, at least 3 years, at least 4 years, or at least 5 years.

19 . The method of claim 6 , wherein administering the transdermal composition comprises use of a transdermal device.

20 . The method of claim 19 , wherein the transdermal device comprises a transdermal patch selected from a reservoir membrane type patch, a porous membrane type patch, or a solid matrix type patch.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2023
From: MISSLING, CHRISTOPHER U.
To: ANAVEX LIFE SCIENCES CORP.
Reel/Frame 066117/0343 →
Continuity (6)
Continuation 17890083 · Aug 17, 2022
Continuation 17145073 · Jan 8, 2021
Continuation 16717921 · Dec 17, 2019
Continuation 16068703 · Jan 24, 2017
Provisional Application 62287062 · Jan 26, 2016
Related Publication 20240066003A1 · Feb 29, 2024
References Cited (58)
US 7994127B2 · Sur et al. · 2011 [cited by applicant]
US 9180106B2 · Vamvakides · 2015 [cited by applicant]
US 10507196B2 · Missling · 2019 [cited by applicant]
US 10888543B2 · Missling · 2021 [cited by applicant]
US 11446275B2 · Missling · 2022 [cited by applicant]
US 20100069484A1 · Vamvakides · 2010 [cited by applicant]
US 20150152410A1 · Krieg et al. · 2015 [cited by applicant]
US 20150265554A1 · Roux et al. · 2015 [cited by applicant]
US 20150359759A1 · Katz · 2015 [cited by applicant]
AU 2013262709A1 · 2015 [cited by applicant]
CA 2873779A1 · 2013 [cited by applicant]
EA 201390616A1 · 2013 [cited by applicant]
EP 3485882A1 · 2019 [cited by applicant]
EP 2850190B1 · 2020 [cited by applicant]
GR 1002616B · 1997 [cited by applicant]
GR 1004208B · 2003 [cited by applicant]
GR 1005865B · 2008 [cited by applicant]
GR 1006794B · 2010 [cited by applicant]
KR 20140041387A · 2014 [cited by applicant]
WO 9730983A1 · 1997 [cited by applicant]
WO 2008153929A1 · 2008 [cited by applicant]
WO 2014117089A1 · 2014 [cited by applicant]
WO WO2019222754A1 · 2019 [cited by examiner]
Maurice, Tangui. “Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments.” Behavioural brain research 296 (2016): 270-278. (Yea… [cited by examiner]
Bello, Olivia, et al. “Is memantine a potential therapeutic for Rett syndrome ?.” Frontiers in neuroscience 7 (2013): 245. (Year: 2013). [cited by examiner]
Kaufmann, Walter E., et al. “ANAVEX® 2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome.” Pharmacology Biochemistry and Behavior 187 (2019): 172796. (Y… [cited by examiner]
Malar, Dicson S., et al. “Targeting sigma receptors for the treatment of neurodegenerative and neurodevelopmental disorders.” CNS drugs 37.5 (2023): 399-440. (Year: 2023). [cited by examiner]
Collina, Simona, et al. “Sigma receptor modulators: a patent review.” Expert opinion on therapeutic patents 23.5 (2013): 597-613. (Year: 2013). [cited by examiner]
Anavex Life Sciences, “Assessment of ANAVEX 2-73 in a MECP2 Rett Syndrome Mouse Model,” Epilepsy Pipeline Conference, Feb. 26, 2016 [Retrieved on Mar. 24, 2017], 20 pages, Retrieved from the Internet: URL: http://www.an… [cited by applicant]
European Communication pursuant to Article 94(3) EPC received for European Patent Application No. 17703579.7, dated Apr. 17, 2020, 4 pages. [cited by applicant]
Extended European Search Report for European Application No. 22189051.0, mailed on Oct. 28, 2022, 11 pages. [cited by applicant]
Fitzgerald P.M., et al., “Rett Syndrome and Associated Movement Disorders”, Movement Disorders, 1990, vol. 5, No. 3, pp. 195-202. [cited by applicant]
Gianti E., et al., “Chapter 7—Structure-Activity Relationships and Drug Design,” in Remington: The Science and Practice of Pharmacy, 23rd Edition, Pharmaceutical Chemistry, 2021, pp. 129-153. [cited by applicant]
Guy J., et al., “Reversal of Neurological Defects in a Mouse Model of Rett Syndrome,” Science, 2007, vol. 315, No. 5815, 11 pages. [cited by applicant]
Hagebeuk E., et al., “UvA-DARE (Digital Academic Repository),” Rett Syndrome: Neurologic and metabolic aspects—PhD thesis, Nov. 7, 2013, pp. 12-33, URL:https://pure.uva.nl/ws/files/2312678/129068_05.pdf, on Mar. 24, 201… [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/014702, mailed Aug. 9, 2018, 10 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/014702, mailed Apr. 4, 2017, 13 pages. [cited by applicant]
Lisak R.P., et al., “Sigma-1 Receptor Agonists as Potential Protective Therapies in Multiple Sclerosis,” Journal of Neuroimmunology, 2020, vol. 342, No. 577188, 10 pages. [cited by applicant]
Lombardi L.M., et al., “MECP2 Disorders: from the Clinic to Mice and Back,” The Journal of Clinical Investigation, Aug. 2015, vol. 125, No. 8, pp. 2914-2923. [cited by applicant]
Lotan M., et al., “Rett Syndrome: Therapeutic Interventions (Disability Studies),” Nova Science Publishers, Inc., 1st Ed, 2011, PMID: 26060191, 1 page. [cited by applicant]
Loviglio M.N., et al., “Identification of a RAI1-Associated Disease Network Through Integration of Exome Sequencing, Transcriptomics, and 3D Genomics,” Genome Medicine, 2016, vol. 8, No. 105, pp. 1-15. [cited by applicant]
Lyst M.J., et al., “Rett Syndrome: a Complex Disorder with Simple Roots,” Nature Reviews Genetics, GB, Mar. 3, 2015, vol. 16(5), pp. 261-275, doi:10.1038/nrg3897, ISSN 1471-0056, XP055358535. [cited by applicant]
Mallon A.M., et al., “EuroPhenome and EMPReSS: Online Mouse Phenotyping Resource,” Nucleic Acids Research, Sep. 28, 2007, vol. 36, pp. D715-D718. [cited by applicant]
Morgan H., et al., “EuroPhenome: A Repository for High-throughput Mouse Phenotyping Data,” Nucleic Acids Research, Nov. 23, 2009, vol. 38, pp. D577-D585. [cited by applicant]
Office Action for Canadian Application No. 3,012, 199, mailed on Mar. 10, 2023, 4 pages. [cited by applicant]
Office Action for Japanese Patent Application No. 2018-536130, mailed on Nov. 30, 2020, 7 Pages. [cited by applicant]
Office Action for Japanese Patent Application No. 2021-010835, mailed on Jan. 7, 2022, 6 Pages. [cited by applicant]
Office Action for Japanese Patent Application No. 2022-153402, mailed on Aug. 16, 2023, 7 Pages. [cited by applicant]
Pohodich A.E., et al., “Rett Syndrome: Disruption of Epigenetic Control of Postnatal Neurological Functions,” Human Molecular Genetics, Jun. 9, 2015, vol. 24, No. R1, pp. 1-19. [cited by applicant]
Rafati M., et al., ““Familial” versus “Sporadic” Intellectual Disability: Contribution of Common Microdeletion and Microduplication Syndromes,” Molecular cytogenetics, 2012, vol. 5, No. 9, pp. 1-5. [cited by applicant]
Rebowe N., et al., “Anavex 2-73 as a Potential Treatment for Rett Syndrome and Other Pediatric or Infantile Disorders with Seizure Pathology,” Rett Syndrome Symposium, Jun. 22-24, 2016, pp. 1-30, Retrieved from the Inte… [cited by applicant]
“Rett Syndrome Fact Sheet, NIH Publication No. 09-4863,” National Institute of Neurological Disorders and Stroke (NINDS), Nov. 2009, 3 pages. [cited by applicant]
Ricceri L., et al., “Mouse Models of Rett Syndrome: From Behavioural Phenotyping to Preclinical Evaluation of New Therapeutic Approaches,” Behavioural Pharmacology, 2008, vol. 19, No. 56, pp. 501-517. [cited by applicant]
Tan W-H., et al., “Pharmacological Therapies for Angelman Syndrome,” Wiener Medizinische Wochenschrift, Jan. 12, 2016, vol. 167, No. 9, 14 pages. [cited by applicant]
Trappe R., et al., “MECP2 Mutations in Sporadic Cases of Rett Syndrome Are Almost Exclusively of Paternal Origin,” The American Journal of Human Genetics, May 2001, vol. 68, No. 5, pp. 1093-1101. [cited by applicant]
Tropea D., et al., “Partial Reversal of Rett Syndrome-like Symptoms in MeCP2 Mutant Mice,” Proceedings of the National Academy of Sciences, Feb. 10, 2009, vol. 106, No. 6, pp. 2029-2034, XP055122225. [cited by applicant]
Villard V., et al., “Anti-Amnesic and Neuroprotective Potentials of the Mixed Muscarinic Receptor/Sigma1 (σ1) Ligand ANAVEX2-73, a Novel Aminotetrahydrofuran Derivative,” Journal of Psychopharmacology, Aug. 2011, vol. 2… [cited by applicant]
Wright R., “Molecular Mechanisms: Rett, Angelman Genes Work Together,” Spectrum, Autism Research News, Aug. 13, 2023, pp. 1-2. [cited by applicant]